Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

48.19 -0.57 (-1.17%)

Streaming Delayed Price Updated: 12:58 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	321,875
Open	48.70
Bid (Size)	48.11 (100)
Ask (Size)	48.20 (100)
Prev. Close	48.76
Today's Range	48.05 - 49.19
52wk Range	29.08 - 65.00
Shares Outstanding	93,706,790
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗

June 03, 2026

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Via The Motley Fool

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

June 02, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Performance

YTD	+3.7%	+3.7%
1 Month	-13.4%	-13.4%
3 Month	-17.3%	-17.3%
6 Month	+4.6%	+4.6%
1 Year	+42.4%	+42.4%

More News

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Via The Motley Fool

Vaxcyte Inc (NASDAQ:PCVX) Reports Q4 2025 Results, Highlights Phase 3 Progress and Strong Cash Position ↗

February 24, 2026

Via Chartmill

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

Via The Motley Fool

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally ↗

May 18, 2026

Via The Motley Fool

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

May 06, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

April 07, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

March 23, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

Via The Motley Fool

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

Via The Motley Fool

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

March 18, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

Via MarketMinute

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 24, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

February 11, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

February 10, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

February 05, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 02, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Pricing of $550 Million Public Offering

January 29, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 29, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

January 22, 2026

From Vaxcyte, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Vaxcyte, Inc. - Common Stock publicly traded?

Yes, Vaxcyte, Inc. - Common Stock is publicly traded.

What exchange does Vaxcyte, Inc. - Common Stock trade on?

Vaxcyte, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vaxcyte, Inc. - Common Stock?

The ticker symbol for Vaxcyte, Inc. - Common Stock is PCVX on the Nasdaq Stock Market

What is the current price of Vaxcyte, Inc. - Common Stock?

The current price of Vaxcyte, Inc. - Common Stock is 48.19

When was Vaxcyte, Inc. - Common Stock last traded?

The last trade of Vaxcyte, Inc. - Common Stock was at 06/05/26 12:58 PM ET

What is the market capitalization of Vaxcyte, Inc. - Common Stock?

The market capitalization of Vaxcyte, Inc. - Common Stock is 4.52B

How many shares of Vaxcyte, Inc. - Common Stock are outstanding?

Vaxcyte, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.